4th Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$580,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA Re-negotiation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); White House Office; SENATE; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax Medical Device Tax Repeal & Suspension Section 385 Tax Regulation Tax Reform Orphan Drug Tax Tax Reform Border Adjustment Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Interest Deduction Debt Equity Regulations Tax Cuts & Jobs Act Implementation Innovation Box Expanded FDII

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Health & Human Services, Dept of (HHS); White House Office; State, Dept of (DOS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA)

Copyright/Patent/Trademark CPT

Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH New —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: White House Office; U.S. Agency for International Development (USAID); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Office of Management & Budget (OMB)

Health Issues HCR

H.R.6948 - Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 Cell & Gene Therapy, including reimbursement Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs IPAB Generic Drug Labeling Outcomes-based Contracting PREA/BPCA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017 and related legislation Drug Compounding CMMI H.R.2641 - Promoting Life-Saving New Therapies for Neonates Act of 2017 Clinical Trials H.R.2430 - FDA Reauthorization Act of 2017 H.R.849 - Protecting Seniors' Access to Medicare Act of 2017 Virtual Clinical Trials S2465 - Sickle Cell Disease Part D Donut Hole PAUSE Act DQSA Implementation Omnibus bill CR PAHPA Reauthorizing Biosimilar Pass Through Payments Value Based Pricing

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: White House Office; State, Dept of (DOS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); SENATE

Bills named: H.R. 6948 (115th), S. 456 (115th), H.R. 849 (115th), S. 469 (115th), H.R. 2430 (115th), S. 204 (115th), H.R. 2641 (115th)

Foreign Relations FOR

Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform Treasury

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; U.S. Agency for International Development (USAID); State, Dept of (DOS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; White House Office

Medicare/Medicaid MMM

Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: State, Dept of (DOS); White House Office; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); U.S. Agency for International Development (USAID); SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2018 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars 2018 Agriculture Appropriations Bill Importation Drug Pricing Value of Meds

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: SENATE; White House Office; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.